Mary Lynne Hedley

About

A scientist by training who focuses on new company formation and therapeutic discovery and development, keeping patients central to her work. She co-founded and co-led TESARO before its acquisition by GSK and has held executive leadership roles across biotech and pharma, developing medicines primarily for cancer patients. She holds a B.S. from Purdue, a Ph.D. in Immunology from UT Southwestern, and completed post-doctoral fellowships at Harvard; she joined the firm in 2023.